Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) Other Non Operating Income (2023 - 2025)

Historic Other Non Operating Income for Evoke Pharma (EVOK) over the last 3 years, with Q3 2025 value amounting to -$18520.0.

  • Evoke Pharma's Other Non Operating Income rose 3072.23% to -$18520.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$34147.0, marking a year-over-year increase of 8625.72%. This contributed to the annual value of -$148057.0 for FY2024, which is 5903.28% up from last year.
  • Per Evoke Pharma's latest filing, its Other Non Operating Income stood at -$18520.0 for Q3 2025, which was up 3072.23% from -$12124.0 recorded in Q2 2025.
  • Evoke Pharma's Other Non Operating Income's 5-year high stood at $932.0 during Q4 2024, with a 5-year trough of -$99483.0 in Q4 2023.
  • Over the past 3 years, Evoke Pharma's median Other Non Operating Income value was -$26733.0 (recorded in 2024), while the average stood at -$41454.3.
  • As far as peak fluctuations go, Evoke Pharma's Other Non Operating Income soared by 10093.68% in 2024, and later skyrocketed by 3072.23% in 2025.
  • Quarter analysis of 3 years shows Evoke Pharma's Other Non Operating Income stood at -$99483.0 in 2023, then soared by 100.94% to $932.0 in 2024, then tumbled by 2087.12% to -$18520.0 in 2025.
  • Its last three reported values are -$18520.0 in Q3 2025, -$12124.0 for Q2 2025, and -$4435.0 during Q1 2025.